Varian
Medical Systems, Inc. are engaged in the design, manufacture, sale and service
of equipment and software products for treating cancer with radiotherapy,
stereotactic radiotherapy, stereotactic body radiotherapy (SBRT), stereotactic
radiosurgery (SRS) and brachytherapy. The Company also designs, manufactures,
sells and services x-ray tubes for original equipment manufacturers (OEMs);
replacement x-ray tubes, and flat panel digital image detectors for filmless
x-ray imaging (flat panel detectors or digital image detectors) in medical,
dental, veterinary, scientific and industrial applications. It designs,
manufactures, sells and services linear accelerators, digital image detectors,
image processing software and image detection products for security and
inspection purposes. In March 2011, it acquired a privately-held supplier of
devices for delivery of brachytherapy treatment of cancer. In August 2012, the
Company established a subsidiary, Varian Medical Systems Korea.
What’s Going
With VAR? Find Out Here:
Varian Medical Techniques (NYSE: VAR )
increased 16%, after its every one
fourth results and assistance easily lead Wall Road objectives. Varian stocks have declined this year on poor
income growth, but modern broader fourth-quarter defeat -- modified EPS of
$1.08 on income of $756 thousand in comparison to the agreement of $1.03 and
$747 thousand, respectively -- and high energy assistance are pushing experts
to increase their assessment reports. Sales of its oncology systems and X-ray
product sections increased a strong 7% and 9%, respectively, indicating that
overall need is much better than Mr. Market had previously thought.
Management
now recognizes 2013 EPS of $4.06-$4.16 and income development of 8%-9%.
"Our organization is placed for development by concentrating on ongoing
advancement, growing our international existence, developing our application
and assistance operations and commercializing protons," CEO Dow Wilson
said in a declaration. More essential, with the inventory still off its 52-week
peaks and dealing at a ahead P/E of 15, there might still be enough space to
buy into that development.
